Rosenblum Mark J
Chief Financial Officer
Rosenblum Mark J has filed 2 SEC Form 4 filings (2 transaction rows) across 2 companies, including DCOY, SLRX, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Sep 2, 2026.
On the most recent filing, Rosenblum Mark J is listed as Exec VP Finance, CFO at Salarius Pharmaceuticals, Inc. Inside the rolling window, Rosenblum Mark J reported 1 open-market purchase totaling $16K in SLRX and no open-market sales.
Companies traded
Other insiders at DCOY
Insider Buying
$16K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Rosenblum Mark J made?
Rosenblum Mark J has filed 2 SEC Form 4 filings (2 transaction rows) across 2 companies, including DCOY, SLRX since 2025.
Which companies does Rosenblum Mark J trade?
Rosenblum Mark J has filed SEC Form 4 disclosures for 2 companies, including DCOY, SLRX.
When was Rosenblum Mark J's most recent SEC Form 4 filing?
Rosenblum Mark J's most recent SEC Form 4 filing on Tracefour is dated Sep 2, 2026.
What is Rosenblum Mark J's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Rosenblum Mark J is listed as Chief Financial Officer.
What is Rosenblum Mark J's total buy and sell value in the current window?
Inside the rolling retention window, Rosenblum Mark J bought $16K and sold $0 based on SEC Form 4 filings.
What was Rosenblum Mark J's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 20,000 SLRX shares on 2025-11-20, worth $16K, per SEC Form 4 filings.